Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.
紐約，2025年1月7日（全球新聞網）-- Lexeo Therapeutics, Inc.（納斯達克：LXEO）是一家致力於爲基因確定的心血管疾病開創治療方法的臨牀階段基因醫學公司，今天宣佈其首席執行官R. Nolan Townsend將於2025年1月15日星期三太平洋時間上午8:15在加利福尼亞州舊金山舉行的第43屆摩根大通醫療健康會議上進行演講。
The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the website following the presentation.
該活動將在公司網站的投資者部分的資訊與活動標籤下進行現場直播。演講結束後，網站上將提供重播。
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer's disease programs.
關於Lexeo治療學
Lexeo Therapeutics是一家總部位於紐約市的臨牀階段基因醫學公司，致力於通過應用開創性科學來改變醫療保健，根本改變基因確定的心血管疾病和與APOE4相關的阿爾茨海默病的治療方法。Lexeo採用逐步開發的方法，利用早期概念驗證的功能和生物標誌物數據，推動心血管和與APOE4相關的阿爾茨海默病項目的進展。
Media Response:
media@lexeotx.com
媒體回應：
media@lexeotx.com
Investor Response:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com
投資者回應：
卡洛·坦齊，博士。
ctanzi@kendallir.com
譯文內容由第三人軟體翻譯。
